NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.17
+3.96%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$1.49
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$1.53
- EPS estimate
- -$1.42
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +4.0%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $93
- PT range
- $60 – $166
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$1.42 | -$1.53 | Miss -7.75% | — |
| May 12, 2026 | -$1.30 | -$1.39 | Miss -7.23% | — |
| Mar 24, 2026 | -$1.24 | -$1.12 | Beat 9.59% | — |
| Nov 13, 2025 | -$1.26 | -$0.99 | Beat 21.43% | — |
| May 9, 2025 | -$1.05 | -$1.08 | Miss -2.86% | — |
| Mar 24, 2025 | -$1.04 | -$0.99 | Beat 4.81% | — |
| Nov 18, 2024 | -$1.22 | -$1.19 | Beat 2.46% | — |
| Aug 9, 2024 | -$1.02 | -$1.09 | Miss -6.86% | $925.0K |
| May 10, 2024 | -$1.03 | -$1.00 | Beat 2.91% | — |
| Nov 14, 2023 | -$0.80 | -$0.41 | Beat 48.75% | — |
| Aug 10, 2023 | -$0.15 | -$0.04 | Beat 73.33% | — |
| Mar 30, 2019 | — | -$0.09 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026